CRL
NYSECharles River Laboratories International Inc.
Price$300.23-7.65 (-2.48%)
01:30 PM07:45 PM
News · 26 weeks80+60%
2026-04-192026-10-11
Mix3190d
- Insider13(42%)
- Other11(35%)
- Analyst3(10%)
- SEC Filings3(10%)
- Earnings1(3%)
Latest news
25 items- PRCharles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine DevelopmentCollaboration leverages next-generation sequencing (NGS) services to advance development and commercialization of an off-the-shelf therapy for osteoarthritis and future programs Charles River Laboratories International, Inc. (NYSE:CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and release testing, and extensive development support service
- PRCharles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference CallCharles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2026 financial results on Wednesday, November 4th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 4th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe a
- INSIDERSEC Form 4 filed by Charles River Laboratories International Inc.4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- PRCharles River and Autolomous Partner to Transform Laboratory Execution SystemsPartnership reinforces continued investment in digitization, automation, and client-facing transparency Charles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orchestrate™ marks a significant milestone in the Company’s broader, ongoing transition toward a fully digital laboratory experience which is conn
- INSIDEREVP & Chief Financial Officer Coleman Glenn bought $2,974 worth of shares (10 units at $297.43), increasing direct ownership by 0.04% to 27,762 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- ANALYSTUBS resumed coverage on Charles River with a new price targetUBS resumed coverage of Charles River with a rating of Buy and set a new price target of $357.00
- SECCharles River Laboratories International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- PRCharles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day– Outlines Pathway to Purpose Strategy to Modernize the Company, Strengthen Its Scientific Portfolio, and Enhance the Client Experience – – Issues Long-Term Financial Targets through 2030 – – Reaffirms 2026 Financial Guidance with Revenue and Non-GAAP Earnings per Share Expected at the Upper Ends of Prior Ranges – Charles River Laboratories International, Inc. (NYSE:CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET. Birgit Girshick, Chief Executive Officer, along with members of the senior management team, will highlight a refreshed strategic vision, Pathway to Purpose, to modernize the Company, strengthen its scientific portfolio, and drive pr
- PRCharles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking TimelinesCharles River platform offers 40% reduction in cell bank production timeline, over the industry standard of 20 weeks Charles River Laboratories International, Inc. (NYSE:CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensive, end-to-end solution that enhances product quality, safety, and regulatory readiness while reducing overall developm
- PRCharles River Laboratories to Present at Morgan Stanley and Baird ConferencesCharles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, at 10:00 a.m. ET; and Baird 2026 Global Healthcare Conference on Tuesday, September 15th, at 9:40 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after eac
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- PRCharles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production SuiteEnhanced automation delivers improved traceability and capacity, while increasing manufacturing efficiency Charles River Laboratories International, Inc. (NYSE:CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced manufacturing technologies, designed to strengthen product quality and support the growing demands of customers worldwide. Th
- INSIDERDirector Foster James C exercised 33,561 shares at a strike of $199.42 and sold $10,068,300 worth of shares (33,561 units at $300.00) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERChief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERDirector Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- PRCharles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation SequencingCollaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testing Charles River Laboratories International, Inc. (NYSE:CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent enterovirus vaccine. The collaboration reflects both companies' shared commit
- INSIDERChief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCEVP, Disc & Safety Assessment Parisotto Shannon M exercised 3,714 shares at a strike of $179.66 and sold $1,038,657 worth of shares (3,714 units at $279.66) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.SCHEDULE 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- INSIDEREVP, Corp Strategy & Develop Laplume Joseph W gifted 257 shares, decreasing direct ownership by 0.82% to 31,041 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERDirector Foster James C exercised 28,733 shares at a strike of $179.66 and sold $7,901,575 worth of shares (28,733 units at $275.00) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERSVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDEREVP & Chief People Officer Creamer Victoria L sold $1,083,030 worth of shares (4,179 units at $259.16) and exercised 4,179 shares at a strike of $179.66 (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCEVP, Disc & Safety Assessment Parisotto Shannon M sold $1,327,098 worth of shares (5,046 units at $263.00) as part of a pre-agreed trading plan, decreasing direct ownership by 51% to 4,807 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
CRL FAQ
7 questionsWhat does Charles River Laboratories International Inc. do?
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of...Where does CRL stock trade?
Charles River Laboratories International Inc. (CRL) is listed on NYSE.What sector and industry is CRL in?
Charles River Laboratories International Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Charles River Laboratories International Inc. go public?
Charles River Laboratories International Inc. (CRL) completed its IPO in 2000.What are analysts saying about CRL?
Charles River Laboratories International Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-30.What companies are similar to CRL?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), MEDP (Medpace Holdings Inc.), PPD (PPD, Inc.), ICLR (ICON plc). Compare CRL side-by-side with any of them on Quantisnow.How can I track CRL on Quantisnow?
Quantisnow aggregates Charles River Laboratories International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRL to receive live email and push alerts on every new disclosure.